Format

Send to

Choose Destination
Oncol Lett. 2019 Jan;17(1):907-912. doi: 10.3892/ol.2018.9658. Epub 2018 Nov 1.

Efficacy and safety of TE/TEC/intensive paclitaxel neoadjuvant chemotherapy for the treatment of breast cancer.

Author information

1
Department of Surgery, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110000, P.R. China.
2
Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110000, P.R. China.
3
Department of Pediatric Intensive Care Medicine, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110000, P.R. China.
4
Department of Ultrasonography, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110000, P.R. China.
5
Department of Medical Administration, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110000, P.R. China.

Abstract

Efficacy and safety of paclitaxel/docetaxel + epirubicin (TE), paclitaxel/docetaxel + epirubicin + cytoxan (TEC) and intensive paclitaxel (IP) neoadjuvant chemotherapy (NCT) were compared for the treatment of breast cancer. The clinical data of 326 patients with stage II-III unilateral primary breast cancer treated in Shengjing Hospital of China Medical University from January 2012 to April 2016 were retrospectively analyzed. All patients received NCT for 4 cycles, including 115 cases of TE group, 109 cases of TEC group, and 102 cases of paclitaxel weekly group. The clinical efficacy was evaluated and complete response (CR) + partial response (PR) indicated clinically effective. The pathological effect was evaluated and the grade III+IV+V indicated pathologically effective. The rates of clinical efficacy and pathological CR (pCR) were compared, and the incidence of adverse reactions was also observed. The effects of different molecular typing on clinical efficacy and pCR were compared. Our results showed that the clinical effective rates in TE, TEC and IP groups were 80.9, 89.0 and 77.5%, respectively, and there were no statistically significant differences (P=0.074). The pCR rates in the three groups were 9.57, 8.26 and 5.88%, respectively, and the differences were not statistically significant (P=0.602). The incidence rate of neutropenia was statistically different among the three groups of patients (P<0.001), which was the highest in TEC group and the lowest in IP group. There were no statistically significant differences in the incidence rates of adverse reactions (P>0.05). Estrogen receptor (ER)-negative, progesterone receptor (PR)-negative and human epidermal growth factor receptor-2 (HER-2)-positive states were significantly correlated with the high clinical effective rate and high pCR rate (P<0.05). In conclusion, IP has the lowest incidence rate of neutropenia. Additionally, ER-negative, PR-negative and HER-2-positive states are significantly correlated with the high clinical effective rate and high pCR rate.

KEYWORDS:

adverse reactions; breast cancer; efficacy; molecular typing; neoadjuvant chemotherapy; paclitaxel

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center